respiratori
viral
infect
rvi
import
hematopoiet
stem
cell
transplant
hsct
knowledg
regard
incid
morbid
mortal
longterm
pulmonari
complic
limit
report
studi
evalu
incid
outcom
short
longterm
rvi
children
receiv
hsct
januari
decemb
patient
underw
hematopoiet
stem
cell
transplant
hsct
hospit
sick
children
allogen
autolog
screen
caus
death
first
year
hsct
patient
found
rvi
caus
death
evid
first
day
hsct
fiftyfour
patient
found
rvi
within
first
day
hsct
allogen
autolog
upper
lower
respiratori
tract
infect
document
patient
respect
virus
parainfluenza
respiratori
syncyti
viru
influenza
adenoviru
human
metapneumoviru
coronaviru
rhinoviru
three
patient
relaps
primari
diseas
day
exclud
overal
mortal
remain
patient
allogen
autolog
death
directli
attribut
rvi
death
occur
patient
lower
respiratori
tract
infect
remain
patient
follow
median
year
rang
chronic
pulmonari
complic
observ
clear
season
pattern
contract
rvi
evid
total
rvi
occur
octob
march
versu
p
given
signific
mortal
rvi
challeng
prevent
choos
time
start
hsct
whenev
possibl
may
help
prevent
rvi
improv
outcom
infect
main
complic
hematopoiet
cell
transplant
hsct
respiratori
viral
infect
rvi
increasingli
recogn
import
complic
hsct
variabl
degre
morbid
mortal
recent
year
grow
number
hsct
util
altern
donor
cord
progenitor
stem
cell
along
common
use
serotherapi
contribut
signific
increas
viral
infect
hsct
wellknown
virus
herp
simplex
viru
hsv
cytomegaloviru
cmv
major
caus
morbid
mortal
hsct
howev
sinc
prophylact
preemptiv
antihsvcmv
therapi
becam
standard
practic
morbid
mortal
hsv
cmv
diseas
rare
nonetheless
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
rsv
continu
major
caus
morbid
mortal
patient
hsct
increas
awar
diagnosi
infect
howev
prophylact
approach
virus
exist
hsct
recipi
henc
studi
aim
investig
incid
risk
factor
rvi
children
hsct
describ
shortand
longterm
outcom
patient
studi
approv
institut
research
ethic
board
medic
record
children
receiv
hsct
januari
biolog
blood
marrow
transplant
j
u
r
n
l
h
e
p
g
e
w
w
w
b
b
r
g
decemb
hospit
sick
children
toronto
review
identifi
patient
posit
test
respiratori
viru
obtain
nasopharyng
aspir
npa
bronchoalveolar
lavag
bal
pleural
tap
lung
biopsi
specimen
microbiolog
test
includ
follow
methodolog
follow
definit
use
studi
upper
respiratori
tract
infect
urti
defin
detect
rvi
upper
respiratori
secret
togeth
symptom
upper
respiratori
tract
nose
throat
lower
respiratori
tract
infect
lrti
defin
either
hypoxia
pulmonari
infiltr
togeth
identif
rvi
upper
respiratori
secret
bal
pleural
tap
lung
biopsi
day
engraft
defin
first
consecut
day
peripher
absolut
neutrophil
count
l
trm
defin
either
due
rvi
transplant
toxic
death
due
rvi
defin
death
respiratori
failur
caus
pneumonia
longterm
pulmonari
complic
defin
limit
pulmonari
statu
includ
pulmonari
function
test
relaps
defin
find
hematolog
cytogenet
recurr
initi
therapi
recurr
progress
diseas
defin
tumor
growth
spread
sinc
undergo
transplant
patient
nurs
protect
isol
singl
room
higheffici
particul
air
filter
patient
indwel
central
venou
cathet
major
receiv
nutrit
support
nasogastr
feed
total
parenter
nutrit
infect
prophylaxi
includ
fluconazol
fungal
prophylaxi
ganciclovir
cmv
prophylaxi
preemptiv
strategi
onward
growth
factor
given
indic
laminar
air
flow
room
use
day
engraft
intraven
immunoglobulin
dose
gkg
supplement
igg
level
less
mgdl
igg
level
routin
monitor
everi
week
patient
pneumocysti
jiroveci
prophylaxi
given
hsct
hsct
least
month
pneumococc
prophylaxi
penicillin
continu
least
year
administr
pneumococc
vaccin
blood
product
transfus
maintain
hemoglobin
concentr
mgl
platelet
count
fever
neutropen
phase
treat
broadspectrum
antibiot
amphotericin
caspofungin
necessari
modifi
subsequ
accord
result
blood
tissu
cultur
patient
receiv
preparatori
regimen
underw
transplant
recov
hospit
examin
medic
team
twice
day
achiev
engraft
patient
respiratori
symptom
investig
presenc
respiratori
virus
chest
radiograph
comput
tomographi
scan
obtain
clinic
indic
npa
throat
swap
nasal
swab
use
obtain
upper
respiratori
specimen
bal
pleural
tap
andor
lung
biopsi
use
obtain
lower
respiratori
specimen
primari
endpoint
studi
review
rviposit
patient
hsct
describ
outcom
term
trm
longterm
pulmonari
complic
univari
logist
regress
model
construct
analyz
impact
risk
factor
trm
within
first
day
includ
transplant
type
allogen
versu
autolog
graft
type
bone
marrow
versu
peripher
blood
stem
cell
versu
cord
blood
util
serotherapi
antithymocyt
globulin
alemtuzumab
mabcampath
genzym
canada
inc
mississauga
ontario
serotherapi
underli
disord
malign
versu
benign
report
p
valu
signific
level
use
statist
analys
carri
use
spss
version
eight
hundr
fortyfour
patient
underw
hsct
hospit
sick
children
toronto
canada
studi
period
compris
studi
popul
transplant
recipi
consist
femal
male
patient
median
age
year
rang
month
year
hsct
allogen
patient
autolog
patient
diseas
hsct
perform
acut
lymphoblast
leukemia
n
acut
myeloid
leukemia
n
myelodysplast
syndrom
n
sever
aplast
anemia
n
inherit
marrow
failur
n
primari
immun
defici
n
nonhodgkin
lymphoma
n
hodgkin
diseas
n
chronic
myelogen
leukemia
n
metabol
diseas
n
hemophagocyt
lymphohistiocytosi
n
brain
tumor
n
solid
tumor
n
thalassemia
n
other
n
studi
period
among
hsct
recipi
patient
rvi
document
screen
caus
death
patient
found
rvi
never
caus
death
day
hsct
first
day
hsct
patient
rvi
patient
focu
studi
diagnosi
condit
regimen
includ
use
serotherapi
describ
tabl
patient
diagnosi
sever
combin
immun
defici
scid
omenn
syndrom
receiv
condit
busulfan
cyclophosphamid
remain
scid
patient
receiv
condit
regimen
analyz
util
serotherapi
found
patient
receiv
antithymocyt
globulin
receiv
alemtuzumab
overal
frequenc
document
rvi
first
day
hsct
frequenc
slightli
higher
allogen
autolog
transplant
p
twentythre
patient
lrti
occur
allogen
patient
autolog
hsct
patient
frequenc
lrti
allogen
autolog
hsct
patient
nineteen
patient
parainfluenza
infect
allogen
autolog
figur
number
patient
contract
rvi
month
display
thirtyf
total
rvi
contract
octob
march
high
flu
season
canada
march
worst
month
compar
posit
rvi
patient
versu
neg
patient
statist
signific
differ
contract
rvi
high
season
versu
low
season
versu
p
eleven
patient
requir
mechan
ventil
parainfluenza
influenza
rsv
adenoviru
four
allogen
autolog
hsct
recipi
die
within
day
transplant
rvi
mechan
ventil
thu
overal
mortal
allogen
autolog
p
none
allogen
transplant
recipi
die
acut
gvhd
two
patient
parainfluenza
infect
die
patient
treat
ribavirin
two
addit
patient
parainfluenza
infect
die
liver
venoocclus
diseas
anoth
pulmonari
hypertens
thu
mortal
caus
parainfluenza
total
mortal
diagnosi
parainfluenza
adenoviru
respiratori
infect
n
patient
die
adenoviru
infect
mortal
caus
adenoviru
infect
one
patient
die
rsv
infect
mortal
caus
rsv
infect
patient
treat
ribavirin
none
patient
influenza
hmpv
coronaviru
rhinoviru
infect
die
respiratori
complic
day
hsct
patient
die
trm
death
relat
respiratori
problem
remain
patient
follow
median
year
rang
chronic
pulmonari
complic
alloimmun
lung
syndrom
observ
two
patient
die
parainfluenza
lrti
patient
wiskottaldrich
syndrom
underw
unrel
cord
blood
transplant
develop
respiratori
distress
day
transplant
npa
posit
parainfluenza
type
antigen
ribavirin
nitric
oxid
highfrequ
oscil
support
given
second
patient
boy
diagnosi
relaps
acut
myeloid
leukemia
underw
match
sibl
bone
marrow
transplant
parainfluenza
type
antigen
posit
npa
day
hsct
patient
develop
acut
respiratori
distress
syndrom
ard
radiograph
find
consist
pneumon
patient
diagnosi
scid
omenn
syndrom
underw
match
sibl
bone
marrow
transplant
patient
develop
ard
rsv
pneumon
day
hsct
two
patient
die
adenoviru
pneumon
ard
patient
diagnosi
neuroblastoma
stage
underw
autolog
hsct
highdos
chemotherapi
patient
delay
engraft
develop
ard
posit
adenoviru
bal
pleural
fluid
anoth
patient
boy
underw
unrel
cord
blood
transplant
sever
aplast
anemia
patient
primari
graft
failur
subsequ
develop
respiratori
distress
requir
highfrequ
oscil
adenoviru
posit
bal
lung
biopsi
type
transplant
graft
type
util
serotherapi
underli
malign
disord
analyz
use
univari
analysi
none
factor
significantli
correl
trm
type
transplant
p
larg
pediatr
studi
found
patient
receiv
allogen
autolog
hsct
posit
rvi
led
overal
mortal
first
day
hsct
mortal
higher
allogen
recipi
compar
autolog
recipi
furthermor
median
followup
year
rang
patient
test
posit
respiratori
viru
die
longterm
pulmonari
complic
patient
contract
viru
day
hsct
advers
event
total
incid
rvi
studi
consist
within
rang
previou
publish
data
pediatr
hsct
recipi
howev
studi
particularli
report
incid
rvi
within
first
day
transplant
distinct
pattern
popul
differ
aforement
studi
data
show
rvi
episod
cluster
within
first
day
transplant
patient
develop
influenza
urti
month
hsct
seriou
respiratori
complic
observ
similar
patient
diagnos
urti
lrti
month
hsct
none
prolong
admiss
die
respiratori
ill
supplement
routin
viral
respiratori
diagnost
pcr
test
adenoviru
pcr
pandem
influenza
pcr
multiplex
respiratori
pcr
request
treat
physician
pcr
proven
specif
sensit
rapid
method
detect
respiratori
virus
compar
antigen
test
viral
cultur
like
respons
increas
rate
detect
though
chang
methodolog
studi
time
frame
mean
test
algorithm
appli
differ
test
methodolog
chang
even
lower
incid
adenoviru
compar
parainfluenza
rsv
infect
studi
respiratoryrel
mortal
higher
adenoviru
ie
patient
confirm
posit
adenoviru
pcr
either
bal
pleural
fluid
lung
biopsi
diagnosi
lrti
moreov
patient
die
sever
pneumon
ard
posit
adenoviru
pcr
test
anoth
appar
caus
respiratori
ill
describ
dissemin
adenoviru
infect
caus
pulmonari
consolid
bacteri
pneumonia
similar
clinic
radiograph
find
adenoviru
infect
may
underrecogn
caus
fatal
pneumonia
immunocompromis
patient
sever
lymphopenia
lymphocyt
dysfunct
likewis
patient
adenoviru
infect
delay
engraft
adenoviru
infect
associ
high
mortal
pediatr
hsct
routin
monitor
adenoviremia
recommend
hsct
asymptomat
reactiv
case
cidofovir
wide
use
preemptiv
therapeut
treatment
adenoviru
infect
despit
wellrecogn
toxic
identif
patient
risk
adenoviru
infect
crucial
immun
reconstitut
key
factor
reactiv
rapid
withdraw
immunosuppress
medic
also
consid
whenev
possibl
respiratoryrel
mortal
parainfluenza
viru
studi
lower
studi
show
approxim
could
explain
earli
year
transplant
complet
mainli
adult
studi
popul
previou
report
larg
retrospect
cohort
studi
fred
hutchinson
cancer
research
center
describ
unrel
transplant
major
risk
factor
parainfluenza
viru
acquisit
well
use
highdos
corticosteroid
patient
die
parainfluenza
viru
pneumonia
diagnosi
wiskottaldrich
syndrom
receiv
methylprednisolon
gvhd
prophylaxi
unrel
cord
blood
transplant
howev
anoth
patient
relaps
acut
myeloid
leukemia
develop
gvhd
receiv
corticosteroid
treatment
aerosol
ribavirin
given
first
patient
given
later
cours
pneumonia
benefit
use
aerosol
ribavirin
treatment
parainfluenza
pneumonia
among
hsct
recipi
controversi
earli
diagnosi
parainfluenza
infect
could
expedit
ribavirin
treatment
initi
improv
outcom
incid
rsv
infect
studi
lrti
compos
one
half
rsv
infect
interestingli
mortal
lower
studi
hsct
recipi
treatment
aerosol
ribavirin
patient
rsv
lrti
may
potenti
reason
lower
mortal
although
fatal
case
observ
patient
receiv
ribavirin
hsct
recipi
high
potenti
progress
urti
sever
lrti
without
welldefin
specif
risk
factor
death
pool
analysi
shah
chemali
suggest
ribavirin
treatment
withwithout
rsvspecif
immunoglobulin
palivizumab
lower
rate
mortal
almost
onethird
review
separ
studi
anoth
small
retrospect
analysi
palivizumab
given
rsv
urti
show
protect
effect
progress
lrti
death
associ
influenza
hmpv
rhinoviru
coronaviru
infect
observ
studi
high
mortal
report
hsct
recipi
influenza
infect
recent
data
show
improv
avail
neuraminidas
inhibitor
inactiv
vaccin
prophylact
approach
influenza
infect
appear
less
effect
hsct
recipi
particularli
first
month
transplant
well
patient
requir
immunosuppress
agent
gvhd
treatment
howev
influenza
vaccin
consid
safe
major
local
gener
advers
effect
report
use
transplant
recipi
hmpv
infect
report
incid
adult
hsct
recipi
patient
hematolog
malign
hmpv
may
associ
sever
pneumonia
fatal
lower
respiratori
tract
diseas
hsct
recipi
even
though
hmpv
infect
document
asymptomat
case
analysi
larger
number
patient
necessari
identifi
real
impact
transplant
popul
human
rhinoviru
coronaviru
despit
high
incid
infect
among
hsct
recipi
morbid
mortal
rel
low
asymptomat
detect
common
account
patient
rhinoviru
coronaviru
respect
mortal
higher
allogen
hsct
recipi
cord
blood
transplant
howev
signific
differ
observ
univari
analysi
previou
studi
reveal
gvhd
use
immunosuppress
agent
major
risk
factor
associ
lrti
mortal
small
number
patient
develop
gvhd
studi
logist
regress
analysi
could
perform
likewis
variou
condit
regimen
use
patient
die
rvi
unabl
establish
correl
transplant
type
respiratori
viruseassoci
death
strength
studi
larg
number
patient
examin
singl
center
uniform
isol
practic
contact
precaut
support
care
limit
retrospect
natur
studi
design
nonetheless
incid
among
hsct
recipi
prospect
studi
could
challeng
use
multipl
center
anoth
challeng
aris
term
isol
practic
infect
precaut
support
care
heterogen
among
hsct
center
final
given
high
mortal
associ
viral
infect
first
day
hsct
studi
may
intuit
avoid
admiss
patient
high
season
respiratori
virus
especi
countri
canada
signific
differ
summer
winter
temperatur
canada
high
season
respiratori
viral
infect
span
octob
march
studi
patient
contract
rvi
high
season
compar
patient
remain
month
may
feasibl
children
need
hsct
urgent
exampl
aggress
leukemia
may
appropri
elect
nonmalign
hsct
minim
risk
acquir
infect
earli
hsct
